We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+46.56%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$44M
(+40%)
Cap. Flow
+$5.06M
Cap. Flow
% of AUM
3.31%
Top 10 Holdings %
Top 10 Hldgs %
41.14%
Holding
109
New
15
Increased
25
Reduced
38
Closed
9
Avg Time Held
3
years
Top 10 Avg Time Held
1.9
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cantaloupe
CTLP
|
+$2.49M |
| 2 |
Biora Therapeutics, Inc. Common Stock
BIOR
|
+$2.43M |
| 3 |
Elutia
ELUT
|
+$1.74M |
| 4 |
SHSP
SharpSpring, Inc.
SHSP
|
+$1.47M |
| 5 |
INTRUSION INC NEW
INTZ
|
+$1.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Magnite
MGNI
|
+$1.29M |
| 2 |
Digital Turbine
APPS
|
+$989K |
| 3 |
BioLife Solutions
BLFS
|
+$909K |
| 4 |
NeoGenomics
NEO
|
+$826K |
| 5 |
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
|
+$802K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.57% |
| 2 | Technology | 13.72% |
| 3 | Communication Services | 8.46% |
| 4 | Industrials | 4.04% |
| 5 | Consumer Staples | 2.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
NeoGenomics
NEO
$2.22B
| $9.76M | 6.38% |
181,250
-18,275
| -9% | -$826K |
2013 Q2
30 quarters
|
|
2
Vericel Corp
VCEL
$2.1B
| $7.81M | 5.11% |
253,037
-23,860
| -9% | -$568K |
2014 Q3
25 quarters
|
|
3
CareDx
CDNA
$3.45B
| $7.81M | 5.11% |
107,792
-11,800
| -10% | -$684K |
2017 Q3
13 quarters
|
|
4
Natera
NTRA
$58.3B
| $6.57M | 4.3% |
66,050
-4,650
| -7% | -$388K |
2018 Q2
10 quarters
|
|
5
Veracyte
VCYT
$3.57B
| $6.22M | 4.07% |
127,080
-3,500
| -3% | -$162K |
2018 Q1
11 quarters
|
|
|
6
Magnite
MGNI
$3.51B
| $5.88M | 3.85% |
191,500
-85,500
| -31% | -$1.29M |
2018 Q2
10 quarters
|
|
7
Idexx Laboratories
IDXX
$43.1B
| $5.55M | 3.63% |
11,105
-100
| -0.9% | -$44.7K |
2013 Q3
29 quarters
|
|
8
Axogen
AXGN
$2.09B
| $4.97M | 3.25% |
277,490
-8,700
| -3% | -$128K |
2013 Q3
29 quarters
|
|
9
OptimizeRx
OPRX
$167M
| $4.88M | 3.19% |
156,688
-12,072
| -7% | -$296K |
2018 Q2
10 quarters
|
|
10
Microsoft
MSFT
$4.01T
| $3.45M | 2.25% |
15,493
-500
| -3% | -$108K |
2014 Q1
27 quarters
|
|
11
DELISTED
FlexShopper
FPAY
| $3.35M | 2.19% |
1,305,530
+88,400
| +7% | +$171K |
2018 Q3
9 quarters
|
|
12
Abbott
ABT
$181B
| $3.02M | 1.98% |
27,580
-450
| -2% | -$48.9K |
2014 Q1
27 quarters
|
|
13
Alphatec Holdings
ATEC
$1.69B
| $2.67M | 1.74% |
183,750
-2,500
| -1% | -$26.4K |
2019 Q3
5 quarters
|
|
|
14
DELISTED
Cantaloupe
CTLP
| $2.67M | 1.74% |
+254,325
| New | +$2.49M |
2020 Q4
0 quarters
|
|
15
DELISTED
Akoustis Technologies Inc
AKTS
| $2.5M | 1.63% |
204,200
+8,900
| +5% | +$78K |
2018 Q4
8 quarters
|
|
16
Rockwell Medical
RMTI
$32.2M
| $2.48M | 1.62% |
22,340
+5,574
| +33% | +$624K |
2013 Q2
30 quarters
|
|
17
Inuvo
INUV
$7.58M
| $2.47M | 1.62% |
545,784
+81,763
| +18% | +$314K |
2018 Q2
10 quarters
|
|
18
DELISTED
BioTelemetry, Inc.
BEAT
| $2.35M | 1.53% |
32,535
-1,700
| -5% | -$89K |
2015 Q3
21 quarters
|
|
19
Castle Biosciences
CSTL
$1.03B
| $2.32M | 1.52% |
34,500
-400
| -1% | -$21.7K |
2019 Q3
5 quarters
|
|
20
Eli Lilly
LLY
$1.12T
| $2.31M | 1.51% |
13,708
-250
| -2% | -$37.3K |
2013 Q2
30 quarters
|
|
21
AtriCure
ATRC
$2.94B
| $2.29M | 1.5% |
41,100
-3,250
| -7% | -$141K |
2013 Q2
30 quarters
|
|
|
CSII
22
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.27M | 1.48% |
51,757
-2,693
| -5% | -$101K |
2013 Q2
30 quarters
|
|
|
SOLO
23
DELISTED
Electrameccanica Vehicles Corp. Ltd.
SOLO
| $2.21M | 1.45% |
357,500
| – | – |
2020 Q3
1 quarter
|
|
24
LeMaitre Vascular
LMAT
$1.9B
| $2.21M | 1.45% |
54,600
-2,100
| -4% | -$75.1K |
2017 Q1
15 quarters
|
|
25
Standard BioTools
LAB
$258M
| $2.21M | 1.45% |
368,400
+35,975
| +11% | +$236K |
2017 Q4
12 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Perkins Capital Management held 109 positions worth $153M, up 40% from $109M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Perkins Capital Management deployed $5.06M of net new capital in Q4 2020, opening 15 new positions and adding to 25 existing holdings. Its largest new stake was Cantaloupe: 254,325 shares worth $2.67M.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 68% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Magnite, an estimated $1.29M trimmed.
- Perkins Capital Management's largest Q4 2020 buy was Cantaloupe: 254,325 shares worth $2.67M.
- Perkins Capital Management added most to Antares Pharma, Inc. in Q4 2020, an estimated $823K increase.
- Perkins Capital Management's biggest Q4 2020 reduction was Magnite, cutting an estimated $1.29M.
- Perkins Capital Management fully exited Digital Turbine in Q4 2020, selling an estimated $989K.
- Perkins Capital Management's ten largest holdings make up 41% of its $153M portfolio in Q4 2020.
- Perkins Capital Management opened 15 new positions and closed 9 in Q4 2020.
- Perkins Capital Management's portfolio value rose 40% quarter-over-quarter to $153M.
Based on Perkins Capital Management's 13F filing for Q4 2020, filed 9 Feb 2021.